Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Angela Joubert James"'
Autor:
Chaofeng Liu, Melanie Patton, Mark R. Litzow, Dale R. Shepard, Erkut Bahceci, Selina Moy, Catherine C. Smith, Angela Joubert James, Zheng Lu, Alexander E. Perl, Kinya Souda, Takeshi Kadokura, Jessica K. Altman, Mark J. Levis
Publikováno v:
Clinical Pharmacokinetics
Clinical pharmacokinetics, vol 59, iss 10
Clinical pharmacokinetics, vol 59, iss 10
Background and Objective Gilteritinib is a novel, highly selective tyrosine kinase inhibitor approved in the USA, Canada, Europe, Brazil, Korea, and Japan for the treatment of FLT3 mutation-positive acute myeloid leukemia. This article describes the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4afe889b7393ad7f418925126988fb4
http://europepmc.org/articles/PMC7550323
http://europepmc.org/articles/PMC7550323
Autor:
Jason J. Luke, Manish Sharma, Sreenivasa R Chandana, Iwona A. Lugowska, Cezary Szczylik, Jakub Zolnierek, Gregory Michael Cote, Charlene Mantia, Rafal Dziadziuszko, Rachel E. Sanborn, Denise Casey, Lori Long, Ashley Ward, Patrick Kaminker, Angela Joubert James, Tiziana Di Pucchio, Bożena Cybulska-Stopa
Publikováno v:
Journal of Clinical Oncology. 41:155-155
155 Background: Lorigerlimab (MGD019) is an investigational, bispecific Fc-bearing (IgG4) DART molecule designed to enhance CTLA-4 blockade on dual expressing, tumor infiltrating lymphocytes, while maintaining maximal PD-1 blockade on PD-1 expressing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b4eb070bce2f57f81f447c1d1f205cfa
https://doi.org/10.1200/jco.2023.41.6_suppl.155
https://doi.org/10.1200/jco.2023.41.6_suppl.155
Autor:
Mark J. Levis, Catherine C. Smith, Angela Joubert James, Melanie Patton, Dale R. Shepard, Mark R. Litzow, Jessica K. Altman, Kinya Souda, Chaofeng Liu, Takeshi Kadokura, Selina Moy, Erkut Bahceci, Alexander E. Perl, Zheng Lu
Publikováno v:
Clinical Pharmacokinetics
Gilteritinib is a novel, highly selective tyrosine kinase inhibitor approved in the USA, Canada, Europe, Brazil, Korea, and Japan for the treatment of FLT3 mutation-positive acute myeloid leukemia. This article describes the clinical pharmacokinetic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5ee8ac6c0f5235998323d8d202fa14a
https://doi.org/10.1007/s40262-021-01060-8
https://doi.org/10.1007/s40262-021-01060-8
Autor:
Ashley Strougo, Solange Corriol-Rohou, Angela Joubert James, Dennis Potempa, Steven J. Kovacs, Raafat Bishai, Christina Bucci-Rechtweg, Jeffrey S. Barrett, Jing Liu, Amy Cheung, Sebastian Haertter, Konstantina M. Vanevski
Publikováno v:
Clinical pharmacology and therapeutics. 103(3)
Extrapolation can be used to address challenges in pediatric drug development. This review describes how these challenges could be addressed by further evolution of quantitative frameworks (i.e., model-based/informed drug discovery and development) a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1675a1866f2329dd40833506348aadba
https://pubmed.ncbi.nlm.nih.gov/29277892
https://pubmed.ncbi.nlm.nih.gov/29277892
Autor:
David F. Claxton, Angela Joubert James, Jessica K. Altman, Alec Goldenberg, Erkut Bahceci, Carsten Mueller-Tidow, Richard A. Larson, Philippe Rousselot, Wanda Knopinska-Posluszny, Elizabeth Shima Rich, Sung-Soo Yoon, Shufang Liu, Fabio Ciceri, Violaine Havelange, Ellen K. Ritchie, Jorge E. Cortes, Mark D. Minden, Tomoki Naoe, Archita Shrivastava, Teresa Bernal del Castillo
Publikováno v:
Journal of Clinical Oncology. 35:TPS7068-TPS7068
TPS7068 Background: Gilteritinib, a highly selective, potent FLT3/AXL inhibitor, showed antileukemic activity with favorable tolerability in a Phase 1/2 trial of FLT3 mutation-positive (FLT3mut+) relapsed/refractory AML. In FLT3mut+ AML cell lines, g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::591c3ad73672fc416f7224120c7eba29
https://doi.org/10.1200/jco.2017.35.15_suppl.tps7068
https://doi.org/10.1200/jco.2017.35.15_suppl.tps7068
Autor:
Lei Shu, Caroline Chen, Nahla Hasabou, Stephen A. Strickland, Giovanni Martinelli, Alexander E. Perl, Richard A. Larson, Jorge E. Cortes, Maria R. Baer, Angela Joubert James, Arnaud Pigneux, Andreas Neubauer, Erkut Bahceci, Ellen K. Ritchie, Philippe Rousselot, Tomoki Naoe, Christoph Röllig
Publikováno v:
Journal of Clinical Oncology. 34:TPS7072-TPS7072
TPS7072Background: FLT3 is the most frequently mutated gene in acute myeloid leukemia (AML) and FLT3 internal tandem duplication (ITD) mutations are associated with high relapse rates, short remiss...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fd2d57ffb133a44639d2f37575cb3492
https://doi.org/10.1200/jco.2016.34.15_suppl.tps7072
https://doi.org/10.1200/jco.2016.34.15_suppl.tps7072
Autor:
Charles Liu, Takeshi Kadokura, Jessica K. Altman, Alexander E. Perl, Catherine C. Smith, Geoffrey Yuen, Angela Joubert James, Peter L. Bonate, Erkut Bahceci, Itsuro Nagase, Ogert Fisniku, Mark J. Levis, Mark R. Litzow, Stan Gill
Publikováno v:
Journal of Clinical Oncology. 34:7026-7026
7026Background: Gilteritinib, also known as ASP2215, is a selective FLT3 inhibitor in development for the treatment of acute myeloid leukemia (AML). In ongoing trials, gilteritinib has demonstrated...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2309647984cefb40187e8cf6257e1c80
https://doi.org/10.1200/jco.2016.34.15_suppl.7026
https://doi.org/10.1200/jco.2016.34.15_suppl.7026